CHANTIX is supplied for oral administration in two strengths: a 0.5 mg capsular biconvex, white to off-white, film-coated tablet debossed with "Pfizer" on one side and "CHX 0.5" on the other side and a 1 mg capsular biconvex, light blue film-coated tablet debossed with "Pfizer" on one side and "CHX 1.0" on the other side. CHANTIX is supplied in the following package configurations:
Description | NDC | |
---|---|---|
Packs | Starting 4-week card: 0.5 mg × 11 tablets and 1 mg × 42 tablets | NDC 0069-0471-03 |
Continuing 4-week card: 1 mg × 56 tablets | NDC 0069-0469-03 | |
Starting Month Box: 0.5 mg × 11 tablets and 1 mg × 42 tablets | NDC 0069-0471-03 | |
Continuing Month Box: 1 mg × 56 tablets | NDC 0069-0469-03 | |
Bottles | 0.5 mg - bottle of 56 | NDC 0069-0468-56 |
1 mg - bottle of 56 | NDC 0069-0469-56 |
CHANTIX is supplied for oral administration in two strengths: a 0.5 mg capsular biconvex, white to off-white, film-coated tablet debossed with "Pfizer" on one side and "CHX 0.5" on the other side and a 1 mg capsular biconvex, light blue film-coated tablet debossed with "Pfizer" on one side and "CHX 1.0" on the other side. CHANTIX is supplied in the following package configurations:
Description | NDC | |
---|---|---|
Packs | Starting 4-week card: 0.5 mg × 11 tablets and 1 mg × 42 tablets | NDC 0069-0471-03 |
Continuing 4-week card: 1 mg × 56 tablets | NDC 0069-0469-03 | |
Starting Month Box: 0.5 mg × 11 tablets and 1 mg × 42 tablets | NDC 0069-0471-03 | |
Continuing Month Box: 1 mg × 56 tablets | NDC 0069-0469-03 | |
Bottles | 0.5 mg - bottle of 56 | NDC 0069-0468-56 |
1 mg - bottle of 56 | NDC 0069-0469-56 |
CHANTIX is supplied for oral administration in two strengths: a 0.5 mg capsular biconvex, white to off-white, film-coated tablet debossed with "Pfizer" on one side and "CHX 0.5" on the other side and a 1 mg capsular biconvex, light blue film-coated tablet debossed with "Pfizer" on one side and "CHX 1.0" on the other side. CHANTIX is supplied in the following package configurations:
Description | NDC | |
---|---|---|
Packs | Starting 4-week card: 0.5 mg × 11 tablets and 1 mg × 42 tablets | NDC 0069-0471-03 |
Continuing 4-week card: 1 mg × 56 tablets | NDC 0069-0469-03 | |
Starting Month Box: 0.5 mg × 11 tablets and 1 mg × 42 tablets | NDC 0069-0471-03 | |
Continuing Month Box: 1 mg × 56 tablets | NDC 0069-0469-03 | |
Bottles | 0.5 mg - bottle of 56 | NDC 0069-0468-56 |
1 mg - bottle of 56 | NDC 0069-0469-56 |
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Contact Medical Information.9AM-5PM ET Monday to Friday; excluding holidays.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.